Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Germany”

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Recruiting
NCT07032662Phase 2Updated Aug 21, 2026
Sponsor: Immunovant Sciences GmbH
Chronic Inflammatory Demyelinating Polyneuropathy
United States, Argentina, Australia, Austria, Belgium +25 more
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)Recruiting
NCT06623422Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
United States, Argentina, Australia, Belgium, Brazil +26 more
Gustabor Phase 1 - AI-based Creation of a Nutritional Plan to Compensate for Chemotherapy-induced Taste DisordersRecruiting
NCT07040189NAUpdated Aug 21, 2026
Sponsor: Wuerzburg University Hospital
Multiple Myeloma · GI Cancer · Taste Disorders
Germany
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusRecruiting
NCT06617325Phase 3Updated Aug 21, 2026
Sponsor: UCB Biopharma SRL
Systemic Lupus Erythematosus
United States, Argentina, Belgium, Canada, Chile +17 more
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)Recruiting
NCT06077760Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
United States, Argentina, Australia, Belgium, Brazil +28 more
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)Recruiting
NCT07174336Phase 3Updated Aug 21, 2026
Sponsor: Eli Lilly and Company
Breast Neoplasms · Neoplasm Metastasis
United States, Argentina, Australia, Belgium, Brazil +14 more
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung CancerRecruiting
NCT07365241Phase 3Updated Aug 21, 2026
Sponsor: AbbVie
Small Cell Lung Cancer
United States, Austria, Germany, Greece, Japan +2 more
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLRecruiting
NCT07007312Phase 3Updated Aug 20, 2026
Sponsor: Kura Oncology, Inc.
Acute Myeloid Leukemia (AML)
United States, Australia, Belgium, Canada, Czechia +11 more
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative ColitisRecruiting
NCT07184996Phase 3Updated Aug 20, 2026
Sponsor: Sanofi
Ulcerative Colitis
United States, Bulgaria, Canada, China, Czechia +15 more
A Study to Test Whether Nerandomilast Helps People With Systemic SclerosisRecruiting
NCT07497087Phase 3Updated Aug 20, 2026
Sponsor: Boehringer Ingelheim
Systemic Sclerosis
United States, Argentina, Australia, Austria, Belgium +40 more
Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition InterventionRecruiting
NCT07649681NAUpdated Aug 20, 2026
Sponsor: Wuerzburg University Hospital
Multiple Myeloma (MM) · GI Cancer · Taste Disorder · Melanoma (Skin Cancer)
Germany
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and ProteinuriaRecruiting
NCT05457283Phase 3Updated Aug 20, 2026
Sponsor: Bayer
Chronic Kidney Disease · Proteinuria · Children
United States, Argentina, Australia, Austria, Belgium +27 more
Prophylactic Reinforcement of Ventral Abdominal Incisions TrialActive Not Recruiting
NCT03911700NAUpdated Aug 20, 2026
Sponsor: C. R. Bard
Open Midline Laparotomy
United States, Austria, Belgium, France, Germany
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusActive Not Recruiting
NCT05531565Phase 2, Phase 3Updated Aug 20, 2026
Sponsor: Biogen
Subacute Cutaneous Lupus Erythematosus · Chronic Cutaneous Lupus Erythematosus
United States, Argentina, Belgium, Brazil, Bulgaria +25 more
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With AcromegalyCompleted
NCT04076462Phase 3Updated Aug 20, 2026
Sponsor: Camurus AB
Acromegaly
United States, Germany, Greece, Hungary, Italy +5 more
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This MedicineActive Not Recruiting
NCT06619509Phase 2Updated Aug 20, 2026
Sponsor: Boehringer Ingelheim
Solid Tumours
United States, Argentina, Australia, Belgium, Canada +15 more
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2Recruiting
NCT07227246Phase 3Updated Aug 20, 2026
Sponsor: Joseph Broderick, MD
Intracerebral Hemorrhage
United States, Canada, Germany, Japan, Spain +1 more
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerActive Not Recruiting
NCT04487080Phase 3Updated Aug 20, 2026
Sponsor: Janssen Research & Development, LLC
Carcinoma, Non-Small-Cell Lung
United States, Argentina, Australia, Belgium, Brazil +23 more
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic RetinopathyActive Not Recruiting
NCT06321302Phase 2Updated Aug 20, 2026
Sponsor: Boehringer Ingelheim
Diabetic Retinopathy
United States, Germany, Hungary, Italy, Japan +4 more
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast CancerActive Not Recruiting
NCT05870579Phase 1Updated Aug 20, 2026
Sponsor: Novartis Pharmaceuticals
Breast Cancer
United States, China, France, Germany, Poland +2 more
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)Active Not Recruiting
NCT04008030Phase 3Updated Aug 20, 2026
Sponsor: Bristol-Myers Squibb
Metastatic Colorectal Cancer
United States, Argentina, Australia, Austria, Belgium +19 more
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLLRecruiting
NCT05197192Phase 3Updated Aug 20, 2026
Sponsor: German CLL Study Group
Chronic Lymphocytic Leukemia
Germany
Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax for Patients With Richter TransformationRecruiting
NCT04271956Phase 2Updated Aug 20, 2026
Sponsor: German CLL Study Group
Richter Transformation
Austria, Denmark, Germany
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)Active Not Recruiting
NCT06185764Phase 1, Phase 2Updated Aug 20, 2026
Sponsor: Vertex Pharmaceuticals Incorporated
Myotonic Dystrophy Type 1 (DM1)
United States, Australia, Belgium, Canada, France +5 more
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF TherapyActive Not Recruiting
NCT05889182Phase 3Updated Aug 20, 2026
Sponsor: AbbVie
Hidradenitis Suppurativa
United States, Argentina, Australia, Austria, Belgium +32 more

Previous page Next page